Novartis Can't Rush Appeal In Elidel FCA Suit, Judge Says

Law360, New York (August 27, 2013, 1:14 PM EDT) -- A Pennsylvania federal judge on Friday denied Novartis Pharmaceuticals Corp.’s request to file an interlocutory appeal on part of her decision trimming down a whistleblower suit alleging the drugmaker defrauded government health care programs by promoting off-label uses of eczema treatment Elidel.

U.S. District Judge Gene E.K. Pratter denied Novartis’ motion to certify a portion of her June 13 decision — in which she declined to dismiss outright the long-running suit from qui tam relator Donald Galmines but stripped the anti-kickback claims and certain state False Claims...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.